ResearchMoz added Latest Research Report titled " Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment " to it's Large Report database.
Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.
A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=799451
Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products are commonly associated with cardiovascular adverse events, and this is further compounded by concerns relating to cancer development through long-term usage of anti-obesity products. This has resulted in an unmet need for products with favorable safety and efficacy profiles, particularly in the case of obesity.
The market size for the diabetes and obesity disease cluster is set to increase considerably, driven by the success of a number of T2DM pipeline products, and a rapidly expanding global patient population. However, obesity pipeline activity is set to remain markedly low, despite a patient population of epidemic proportions.
Browse more details @ http://www.researchmoz.us/global-diabetes-and-obesity-drugs-market-to-2022-insulins-and-gpcrs-retain-commercial-prominence-while-high-unmet-need-remains-in-weight-loss-treatment-report.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.1.1 Diabetes 9
2.1.2 Obesity 10
2.2 Symptoms 11
2.2.1 Diabetes 11
2.2.2 Obesity 11
2.3 Etiology and Pathophysiology 11
2.3.1 Type 1 Diabetes Mellitus 11
2.3.2 Type 2 Diabetes Mellitus 12
2.3.3 Obesity 12
2.3.4 The Association between Obesity and T2DM 13
2.4 Comorbidities and Complications 13
2.5 Epidemiology Patterns and Forecasts across the 7MM 14
2.5.1 Diabetes 15
2.5.2 Obesity 16
2.6 Treatment 17
2.6.1 Diabetic Pharmacotherapeutics 17
2.6.2 Insulin Therapy 18
2.6.3 Amylin Analogs 19
2.6.4 Obesity Pharmacotherapeutics 20
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.
A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=799451
Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products are commonly associated with cardiovascular adverse events, and this is further compounded by concerns relating to cancer development through long-term usage of anti-obesity products. This has resulted in an unmet need for products with favorable safety and efficacy profiles, particularly in the case of obesity.
The market size for the diabetes and obesity disease cluster is set to increase considerably, driven by the success of a number of T2DM pipeline products, and a rapidly expanding global patient population. However, obesity pipeline activity is set to remain markedly low, despite a patient population of epidemic proportions.
Browse more details @ http://www.researchmoz.us/global-diabetes-and-obesity-drugs-market-to-2022-insulins-and-gpcrs-retain-commercial-prominence-while-high-unmet-need-remains-in-weight-loss-treatment-report.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.1.1 Diabetes 9
2.1.2 Obesity 10
2.2 Symptoms 11
2.2.1 Diabetes 11
2.2.2 Obesity 11
2.3 Etiology and Pathophysiology 11
2.3.1 Type 1 Diabetes Mellitus 11
2.3.2 Type 2 Diabetes Mellitus 12
2.3.3 Obesity 12
2.3.4 The Association between Obesity and T2DM 13
2.4 Comorbidities and Complications 13
2.5 Epidemiology Patterns and Forecasts across the 7MM 14
2.5.1 Diabetes 15
2.5.2 Obesity 16
2.6 Treatment 17
2.6.1 Diabetic Pharmacotherapeutics 17
2.6.2 Insulin Therapy 18
2.6.3 Amylin Analogs 19
2.6.4 Obesity Pharmacotherapeutics 20
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
No comments:
Post a Comment